Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer". O'Malley DM, Ledermann JA, Coleman RL. Gynecol Oncol 2023 Feb 9:S0090-8258(23)00049.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

O'Malley DM, Ledermann JA, Coleman RL. Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer". Gynecol Oncol 2023 Feb 9:S0090-8258(23)00049.
PMID: 36774327